<unk>  refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and<unk> sulfan used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).
FLAMSA-BU regimen
ACVBP-R regimen
FMC-R regimen
FLAMSA regimen
RCD regimen
FLAMSA-MEL regimen
FMR regimen
ICE-R regimen